Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Deal Watch: AZ Ups mRNA Stake, Gilead's HIV Innovation, Hospira Returns Lucentis Biosimilar, Pfizer/Takeda End Distribution Deal

Executive Summary

Deal activity over the past week saw AstraZeneca stealthily increase its commitment to mRNA player Moderna, Gilead seek innovation in HIV through an alliance with Genmab for its bispecific antibody technology, and Hospira back out of a licensing deal for Pfenex's Lucentis biosimilar, and more.


Related Content

Moderna Prepares For mRNA Drug R&D Blitz With $474m In New Equity
Advaxis Advances Personalized Cancer Vaccines With Eye On Manufacturing Time, Cost
Versartis Links With Teijin In First Licensing Deal
Pharming Regains Rights To Ruconest, Seizing More Control Over Its Destiny
Deal Worth Up to $464m Advances MEI Drug, Diversifies Helsinn's Portfolio
Ablynx Builds Case For AbbVie Option On Humira Successor
AstraZeneca Ups Betting Ante On Moderna's Messenger RNA Technology
Deal Watch: Endo Hopes To Boost Generics Unit With Buy-Out Of Par
Deal Watch: After Novartis Deal, GSK Increases Vaccine Emphasis With GlycoVaxyn Buyout
Another 2,300 AstraZeneca jobs go but 'simplification will lead to growth', says Soriot


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts